Cardiol Therapeutics Inc. (CRDL.TO)

0.6500 -0.0100 (-1.52%) At close: 03:59PM EDT

Cardiol Therapeutics Inc.

2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada

https://www.cardiolrx.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. David G. Elsley M.B.A., MBA	Pres, CEO & Director	623.76k	N/A	N/A
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA	CFO, Corp. Sec. & Director	239.67k	N/A	N/A
Mr. Bernard Lim B.Sc.	Chief Operating Officer	308.35k	N/A	N/A
Dr. Andrew Warwick Hamer M.D.	Chief Medical Officer & Head of R&D	360.04k	N/A	1962
Trevor Burns	Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Corporate Governance

Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of February 1, 2023 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.